|Day Low/High||57.88 / 58.75|
|52 Wk Low/High||54.17 / 71.04|
Molson Coors is now cheap enough and healthy enough to be a good stock to own.
A shift in the way the central bank manages its balance sheet is dangerous.
Nvidia and Coca-Cola are just two names set to report. Here's what to key in on.
Next week we'll be at the tail end of earnings season. It's been a blast, at least until this past week when we got some iffy news about trade.
Canopy Growth's smoking engine won't necessarily ensure smooth sailing for Constellation.
Even with its 12% stock decline on Wednesday, Constellation Brands is more intriguing than it was yesterday.
In the interest of due diligence, we went and took a close look at the ground floor of the newest investment craze.
Establishing who the stragglers are and what impact they might have in the future is the key at this point.
I'd be most interested in buying this name after a cap raise which I expect in the first quarter of 2019.
Perhaps no company has bought into the Canadian cannabis craze more than Constellation Brands.
Pot stock partnerships are a gateway to gains for cannabis investors.
After Altria's investment in Cronos Group, which cannabis company will be the next target?
Here are 4 stocks that can be bought into the stock cyclone that might occur if things don't go the bulls way in the Argentine.
When the markets get volatile it's time to circle back to defensive stocks.
These stocks offer some diversification or unique features in the legal-weed space.
It's too easy to lump all cannabis-related stocks into the moniker "marijuana." Like many other sectors, there are differentiators underneath the same way we see in semiconductors or retail or even energy. As you go down the marijuana rabbit hole, ...
Covered calls may be the best bet -- or wait for a dip.
Expect more companies to join Coca-Cola, Molson Coors and Constellation Brands in checking out the market.
A tie-up between the two could mark the first major U.S. firm to establish a line of CBD drinks.
The latest reports about Coke looking into cannabis confirms a broader industry trend.
A brewer facing challenges, a banking giant and a retail behemoth are ripe for downside plays.
Not every cannabis stock was strong on Wednesday. One significant Canadian name sure was though.
Moody's and Zacks aren't seeing the potential for CBD drinks or even THC drinks.
Hexo is pursuing joint ventures in cosmetics, health care, candy, edibles, and vape companies.
Tilray reported a 95% jump in second-quarter revenue to $9.7 million, ahead of the Wall Street estimate of $9 million, in its first earnings release since it went public on July 19.
Beer companies are going to greater lengths to grow.
All three major indices closed trading in positive territory Friday.